David McKinsey is an Infectious Disease physician. OpenAlex indexes 59 publications with 3,879 citations (h-index 23).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2340 E Meyer Blvd Bldg 2
Suite 348
Kansas City, MO 641321105
Telephone
816-444-7977Registry record last updated 7 Feb 2019.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ViiV Healthcare CompanyProgram year20257 payments
- GlaxoSmithKline, LLC.Program year20241 payment
- Insmed, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
61.4%Other drugs affecting bone structure and mineralization39.4%Romosozumab-aqqg100%Part B, office-administered≥16 patientsRANK Ligand Inhibitor22%Denosumab100%Part B, office-administered≥89 patientsCardiovascular
21.2%Other lipid modifying agents21.2%Inclisiran100%Part B, office-administered≥16 patientsAnti-infectives
17.3%Lipoglycopeptide Antibacterial14.9%Dalbavancin100%Part B, office-administered≥15 patientsPenem Antibacterial0.5%Ertapenem sodium89%Ertapenem11%Part D + Part B<11 patients+ 14 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- COVID-19 in Missouri 2020-2021: A Perspective on Origins, Spread & Controversies Part II.
PubMed
2022 - A comprehensive approach to ending an outbreak of rare bla gene-positive carbapenem-resistant Acinetobacter baumannii at a Community Hospital, Kansas City, MO, 2018
American Journal of Infection Control
2021 - Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
Drugs - Real World Outcomes
2020
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Yousef Khader
Jordan University of Science and Technology
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Derrick W. Crook
Nuffield Orthopaedic Centre
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”